Table 1.
Baseline characteristics of included mCRPC patients.
| References | Country | Study design | Study period | Tumor type | Treatment | Sample size | Age | Cutoff value | Outcome | Follow-up (months) | NOS SCORE |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bauckneht et al. (20) | Italy | RCS | 2013–2020 | mCRPC | [223Ra] RaCl2 + ADT | 519 | 74 (50–90) | 768.8 | OS | 10.7 | 8 |
| Donate-Moreno et al. (21) | Spain | PCS | Until 2018.12 | mCRPC | AA/EZ | 80 | 72.7 | 535 | OS | 19 [0.43–77.1] | 8 |
| Fan et al. (15) | China | RCS | 2013–2017 | mCRPC | AA-to-DP or DP-to-AA | 104 | 72 [65.3–77.0] | 200 | OS/PFS | 19.2 [17.3–22.3] | 8 |
| Lolli et al. (12) | Italy | RCS | 2011.04–2015.05 | mCRPC | D-to-AA | 230 | 74 (45–90) | 535 | OS | 29 (1–55) | 8 |
| Man and Chen (23) | China | RCS | 2010–2018 | mCRPC | D | 179 | 70 (51–88) | 535 | OS | 24 (2–118) | 8 |
| Kobayashi et al. (22) | Japan | RCS | 2008–2018 | mCRPC | D + ADT | 144 | 71 [65–76] | 636 | OS/PFS | NR | 7 |
| Stangl-Kremser et al. (26) | Austria | RCS | 2005–2016 | mCRPC | D + ADT | 186 | 68.8 [64.6–75.0] | 200 | OS/PFS | 25.5 [12.8–42.4] | 8 |
[ ], interquartile range; ( ), range; AA, abiraterone; ADT, androgen deprivation therapy; D, docetaxel; DP, docetaxel-prednisone; EZ, Enzalutamide; mCRPC, metastatic castration-resistant prostate cancer; NR, Not Reported; OS, overall survival; PCS, prospective cohort study; PFS, progression-free survival; [223Ra] RaCl2, radium-223 dichloride; RCS, retrospective cohort study.
More than 90% of patients included in studies conducted by Kobayashi et al. and Stangl-Kremser et al. were diagnosed with mCRPC and <10% were diagnosed with nmCRPC, so these studies were therefore assigned to the mCRPC group.